{
    "organizations": [],
    "uuid": "587e161d67011b8ff60a0fbdda9ddbcb690685be",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ipsen-announces-ema-validation-of/brief-ipsen-announces-ema-validation-of-filing-of-new-application-for-additional-indication-for-cabometyx-idUSFWN1R90YU",
    "ord_in_thread": 0,
    "title": "BRIEF-Ipsen Announces EMA Validation Of Filing Of New Application For Additional Indication For Cabometyx®",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 28 (Reuters) - IPSEN SA:\n* ANNOUNCES EMA VALIDATION OF FILING OF A NEW APPLICATION FOR ADDITIONAL INDICATION FOR CABOMETYX®, FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC)\n* ‍FILING BASED ON GLOBAL PLACEBO-CONTROLLED PHASE 3 TRIAL RESULTS WHICH MET PRIMARY ENDPOINT OF OVERALL SURVIVAL​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-28T13:10:00.000+03:00",
    "crawled": "2018-03-29T15:55:37.017+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "ipsen",
        "sa",
        "announces",
        "ema",
        "validation",
        "filing",
        "new",
        "application",
        "additional",
        "indication",
        "patient",
        "previously",
        "treated",
        "advanced",
        "hepatocellular",
        "carcinoma",
        "hcc",
        "based",
        "global",
        "phase",
        "trial",
        "result",
        "met",
        "primary",
        "endpoint",
        "overall",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}